; (B) the aggregate amount of gross reimbursement received by the covered entity (calculated before subtracting any administrative or other fees using a methodology provided by the Secretary) for covered outpatient drugs subject to an agreement under this section, including reimbursement received through facilities or organizations described in subsection (c)(3) or pursuant to contractual arrangements described in subsection (a)(11); (C) the aggregate acquisition cost for covered outpatient drugs subject to an agreement under this section dispensed during the year; (D) the aggregate amount paid by the covered entity, or any agent of the covered entity, to contracted entities described in subsection (a)(11) for dispensing covered outpatient drugs subject to an agreement under this section or for any other service related to the drug discount program under this section; (E) how the entity prevents duplicate discounts under subparagraph (A) of subsection (a)(5) and drug diversion under subparagraph (B) of such subsection; (F) the volume of covered outpatient drugs subject to an agreement under this section dispensed by the covered entity and, in the case of a covered entity that has entered into a contractual arrangement pursuant to which a third party dispenses covered outpatient drugs subject to an agreement under this section to patients of the covered entity, by each such contracted entity; (G) quantitative data in terms of the amount and percentage of charitable care, as such term is defined for purposes of Medicare cost reporting or other reporting requirements identified by the Secretary, provided to patients of the covered entity by the covered entity in the form of covered outpatient drugs subject to an agreement under this section; (H) the name of any third-party vendor or other similar entity (if any) that the covered entity retains to administer the covered entity’s inventory management system or contract pharmacy arrangement